74%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Compugen Ltd
Abierto
1.33 1.53
Resumen
Variación precio
24h
Mínimo
1.3
Máximo
1.37
Ingresos | -161K -7.3M |
|---|---|
Ventas | -1M 1.3M |
P/B Media del Sector | 60.333 35.293 |
Margen de beneficios | -584.089 |
Empleados | 74 |
EBITDA | 1M -7.4M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +515.94% upside |
Próximas Ganancias | 11 nov 2025 |
|---|
Capitalización Mercado | -8.5M 130M |
|---|---|
Apertura anterior | -0.2 |
Cierre anterior | 1.33 |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Compugen Ltd Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Compugen Ltd previsión
Precio Objetivo
By TipRanks
515.94% repunte
Estimación a 12 Meses
Media 8.5 USD 515.94%
Máximo 13 USD
Mínimo 4 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Live chat